Research programme: anti-CD55 monoclonal antibodies - Viragen

Alternative Names: CD55 cancer vaccine - Viragen Scotland; CD55 vaccine - Viragen Scotland; VG 102

Latest Information Update: 04 Feb 2008

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cancer Research Technology; University of Nottingham
Developer Viragen Scotland
Class Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD55 antigen inhibitors; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

06 Jun 2007 This programme is still in active development
09 May 2005 The anti-CD55 antibody has been licensed to Viragen worldwide
21 Mar 2005 Preclinical data from a media release have been added to the Cancer pharmacodynamics section

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com